United Therapeutics To Price Oral Treprostinil On Par With Other Formulations
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA labeling for just-approved pulmonary arterial hypertension drug Orenitram (treprostinil) suggests the oral drug could replace United Therapeutics’ other formulations, though it was not specifically studied for that. Company says it was surprised by the approval, which came well ahead of the user fee date, and plans to launch in six months.